Compare AbCellera Biologics Inc (ABCL) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Roundhill Magnificent Seven ETF — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Roundhill Magnificent Seven ETF trades at $65.7. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | MAGS | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $8.12 | $70.94 |
52-Week Low | $2.78 | $55.02 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MAGS (Roundhill Magnificent Seven ETF) trades at $66.28, up 1.81% on the day, with a bullish technical signal driven by moving averages. The ETF holds seven mega-cap tech stocks equally weighted, rebalanced quarterly. Recent news highlights AI-driven market broadening and MAGS's historical outperformance, though 2026 has seen volatility with a drop from YTD highs near $71. RSI_6 at 72.47 suggests short-term overbought conditions.
Outlook: MAGS offers concentrated exposure to leading tech innovators with strong long-term growth potential, but faces risks from high concentration, valuation concerns, and macroeconomic sensitivity. Near-term resistance at $67–68 may cap gains unless earnings momentum accelerates. Diversification benefits are limited due to single-sector focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
